{"schema_version":"secwatch.filing_event.v1","accession":"0001596783-23-000187","form_type":"8-K/A","ticker":null,"cik":"0001596783","company_name":"Catalent, Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.697334+00:00","generated_at":"2026-06-07T15:35:57.762772+00:00","sec_items":["2.02","2.06","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Catalent revises FY2023 and Q1 FY2024 prelim results; goodwill impairment $689M","bullets":["FY2023 Adjusted EBITDA reduced by $17M to $697M; net loss per share widened from $(1.29) to $(1.42).","Q4 FY2023 Adjusted EBITDA fell $17M to $122M; net loss per share increased to $(0.59) from $(0.48).","Q1 FY2024 net loss increased $44M to $759M, including $53M tax valuation allowance; goodwill impairment adjusted to $689M.","Q1 FY2024 Adjusted EBITDA decreased $3M to $112M; adjusted net loss per share $(0.13) vs preliminary $(0.10).","FY2024 guidance unchanged; revisions are non-cash and included in filed 10-K and 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0001596783-23-000187","json":"https://secwatch.observer/filing/0001596783-23-000187.json","markdown":"https://secwatch.observer/filing/0001596783-23-000187.md","text":"https://secwatch.observer/filing/0001596783-23-000187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/ctlt-20231208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:35:57.762772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"717e99c04ef71f63540197ba4e35da487591919b","claim":"Catalent, Inc. reported preliminary financial results for the fourth quarter and fiscal year ended June 30, 2023.","evidence_excerpt":"On August 29, 2023, the Company issued an earnings release setting forth the Company's preliminary fourth quarter and fiscal year ended June 30, 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended June 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"a7b22de17a7171239c388f220aa42675f33aa34e","claim":"Catalent, Inc. reported preliminary financial results for the first quarter ended September 30, 2023.","evidence_excerpt":"In addition, on November 15, 2023, the Company issued an earnings release setting forth the Company's preliminary first quarter ended September 30, 2023 financial results.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended September 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"6a2fb0f8a5ca804f3273b87fb9a5fe6555b91290","claim":"Catalent, Inc. announced a impairment with charges of fixed asset impairment charges primarily associated with an idle facility in the Biologics segment affecting Biologics.","evidence_excerpt":"Revisions to unallocated costs represent fixed asset impairment charges primarily associated with an idle facility in the Biologics segment.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"fixed asset impairment charges primarily associated with an idle facility in the Biologics segment"},{"label":"Affected area","value":"Biologics"}],"fact_type":"restructuring_charge"},{"claim_id":"7e086c4f7b443bfdad1f51c518c17c832b63ee8d","claim":"Catalent, Inc. announced a impairment with charges of $689 million of non-cash goodwill impairment charges affecting Biologics.","evidence_excerpt":"For the three months ended September 30, 2023, unallocated costs include $689 million of non-cash goodwill impairment charges.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1596783/000159678323000187/0001596783-23-000187-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"$689 million of non-cash goodwill impairment charges"},{"label":"Affected area","value":"Biologics"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}